PT  - JOURNAL ARTICLE
AU  - RYU YANAGISAWA
AU  - TOMONOBU KOIZUMI
AU  - TERUTSUGU KOYA
AU  - KENJI SANO
AU  - SHIGEO KOIDO
AU  - KAZUHIRO NAGAI
AU  - MASANORI KOBAYASHI
AU  - MASATO OKAMOTO
AU  - HARUO SUGIYAMA
AU  - SHIGETAKA SHIMODAIRA
TI  - WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
DP  - 2018 Apr 01
TA  - Anticancer Research
PG  - 2217--2225
VI  - 38
IP  - 4
4099  - http://ar.iiarjournals.org/content/38/4/2217.short
4100  - http://ar.iiarjournals.org/content/38/4/2217.full
SO  - Anticancer Res2018 Apr 01; 38
AB  - Background/Aim: Wilms' tumor 1 (WT1) is a tumor-associated antigen highly expressed in cancer. We examined the safety of WT1-peptide pulsed dendritic cell (WT1-DC) vaccine in combination with chemotherapy in patients with surgically resected pancreatic cancer. Patients and Methods: Eight patients with resectable pancreatic cancer undergoing surgery either combined with S-1 or S-1 plus gemcitabine therapy were enrolled. Immunohistochemical analysis of WT1 was performed in 34 cases of pancreatic cancer. Results: No serious side-effects were observed, except grade I fever in five and grade I reactions at the injection site in all patients. WT1-specific cytotoxic T-lymphocytes were detected in seven patients, and WT1 and human leukocyte antigen class I antigens were positive in all 34 cases. Conclusion: Our study clarified the safety and potential acquisition of immunity after vaccination targeting WT1. Further efficacy of WT1-DC vaccine to improve prognosis would be determined by a prospective clinical trial for resectable pancreatic cancer.